Quick Facts About Alcalak

• Addresses: Symptoms related to excess stomach acid.
• Therapeutic Areas: Heartburn, acid indigestion, and sour stomach.
• Other Use: May serve as a calcium supplement to address low blood calcium levels.

---

Alcalak (calcium carbonate) is a treatment used to address gastrointestinal discomfort related to increased acid in the stomach. The use of this medication is indicated for the temporary relief of symptoms such as heartburn, acid indigestion, and sour stomach.

In addition to its role in managing these symptoms, Alcalak may be used to provide calcium supplementation for individuals who may not obtain sufficient calcium from their regular diet. Adequate calcium intake is an essential component for the maintenance of healthy bones and for supporting the regular function of the nervous system and heart.

This section summarizes the official eligibility and contraindication information for Alcalak (Calcium Carbonate) as documented in regulatory labeling.

Populations Who Must NOT Use Alcalak (Contraindications)

• Individuals with known Hypersensitivity to calcium carbonate or any component of the formulation.
• Patients with Hypercalcemia (abnormally high blood calcium levels).
• Patients with severe Renal Impairment or advanced kidney disease, unless specifically directed and monitored by a healthcare provider, due to the risk of calcium accumulation.

Age-Related Eligibility

• Adults and Children 12 years and older: Generally permitted for non-prescription use as directed on the label.
• Children under 12 years: Use is restricted and the label requires the user to “Ask a doctor.”

Conditional Use and Restrictions

Certain populations must consult a health professional before use:

• Patients with a history of kidney stones or conditions associated with high calcium in the urine (Hypercalciuria).
• Women who are pregnant or breastfeeding are advised to “Ask a health professional before use” due to conditional safety and monitoring requirements.
• Individuals with Phenylketonuria (PKU) should check the label, as some formulations may contain a source of phenylalanine.

Interactions with other medicines and products — official regulatory information for Alcalak

Interaction Scope

Classification	Interacting Medicines and Substances
Timing-Separation Required	Levothyroxine, Fluoroquinolone antibiotics (e.g., Ciprofloxacin), Tetracycline antibiotics (e.g., Doxycycline), Bisphosphonates, Iron Supplements, Dolutegravir
Pharmacodynamic Risk	Thiazide Diuretics, Vitamin D Analogues, Cardiac Glycosides
Food/Dietary Interaction	High-calcium foods, Oxalic Acid foods (e.g., spinach), Phytic Acid foods (e.g., whole grains)

Official Interaction Statements

• The co-administration of Alcalak (or any calcium-containing solution) with intravenous ceftriaxone is formally contraindicated due to the risk of precipitate formation.
• Concurrent use with Thiazide Diuretics reduces calcium excretion, which officially leads to an increased risk of hypercalcemia.
• The systemic exposure of co-administered medicines, including Fluoroquinolone antibiotics and Levothyroxine, is officially reduced by Alcalak's action of elevating gastric mathrmpH and via chelation by the calcium ion ( Ca^2+).
• To mitigate reduced absorption, Levothyroxine must be administered at least four hours apart, and Fluoroquinolones must be separated by two hours before or six hours after Alcalak, as mandated by regulatory documents.
• The clinical significance of interactions leading to systemic calcium accumulation is officially noted to be increased in patients with severe renal impairment.

Connection to the overall interaction profile

Regulatory documents define the product's interaction structure primarily through two pharmacokinetic categories: absorption interference due to gastric mathrmpH elevation and binding of other drugs via chelation. This necessitates mandated timing separation rules for multiple drug classes to mitigate the reduction in their systemic exposure. The profile also documents pharmacodynamic interactions that increase the risk of systemic calcium excess.

How Alcalak Works — Mechanism of Action

Immediate Chemical Buffering and pH Modulation

Alcalak’s primary mechanism involves the rapid chemical neutralization of stomach acid within the gastric lumen. The carbonate component targets and consumes free hydrogen ions ( H^+) from hydrochloric acid. This physicochemical reaction rapidly consumes H^+ ions, resulting in a swift, localized rise in the gastric pH .

Indirect Enzyme Inactivation and Downstream Effects

The resulting increase in gastric pH triggers a key downstream physiological effect: the pH-dependent deactivation of the enzyme Pepsin, which requires extreme acidity to function optimally. By inactivating Pepsin, this mechanism reduces the proteolytic capacity of the gastric fluid on the mucosa.

Systemic Mineral Influence and Intestinal Binding

Beyond the stomach, the ionized calcium ( Ca^2+) component is processed. A fraction of the Ca^2+ is absorbed and enters the blood circulation. Unabsorbed Ca^2+ acts locally in the small intestine, binding to dietary anions like phosphate and oxalate, which alters the amount of these minerals available for intestinal absorption.

The medicine Alcalak, formulated as a chewable tablet containing 420 mg of Calcium Carbonate, is administered via the oral route for symptomatic, as-needed management. The intended use is governed by specific dose, frequency, and duration limits designed for short-term, temporary management.

Standard Administration Guidelines

Instruction	Detail
Route and Form	Oral route, requiring the tablet to be chewed or crushed completely before swallowing; the tablet must not be swallowed whole.
Standard Dosing	Adults and Children 12 years and older: The single standard dose is 2 tablets (840 mg CaCO3).
Dosing Frequency	Administration is as-needed when symptoms occur, and the two-tablet dose may be repeated every 2 to 3 hours.
Age Rule	Children under 12 years must not be given this product.
Maximum Limits	The total daily intake must not exceed 19 tablets (7,980 mg CaCO3) in a 24-hour period. The maximum daily dosage should not be used for more than two consecutive weeks.

Procedural Structure and Use Protocol

The administration process is defined by the physical form of the medicine. The mandatory instruction to chew the tablets completely dictates the immediate procedural step before the dose is taken. Dosing frequency follows an as-needed pattern, where intake is conditional on the return of symptoms. The maximum daily dose of 19 tablets and the strict two-week limit on maximum dosage collectively establish that the product is intended for temporary, constrained use. Product labeling also notes that each tablet contains 1.5 mg of Phenylalanine.

Alcalak is a product containing Calcium Carbonate, an inorganic salt. It is primarily studied and used as an antacid to relieve symptoms related to excess stomach acid, such as heartburn, acid indigestion, and sour stomach. Clinical research on the mechanism of action focuses on its ability to neutralize hydrochloric acid in the gastric secretions, which results in an increase in the stomach's pH level. This buffering action is believed to inhibit the activity of pepsin, an enzyme involved in protein digestion that can contribute to mucosal damage.

Findings in Gastrointestinal Relief

Studies comparing calcium carbonate-based antacids to placebo have observed a relationship with the reduction of reported heartburn intensity. One trial investigated the effect of a combination product containing Calcium Carbonate and another acid-reducing agent, noting a reduction in meal-induced heartburn severity in participants, as measured by a Visual Analog Scale (VAS).

Other Uses and Associated Research

Beyond its role as an antacid, Calcium Carbonate is also utilized in clinical settings as a calcium supplement to prevent or manage low calcium levels. Furthermore, in individuals with certain kidney conditions, it is used as a phosphate binder, meaning it helps to manage high phosphate levels by binding to dietary phosphate in the small intestine, which is then excreted from the body.

Safety Profile and Potential Risks

The safety profile of Calcium Carbonate is generally reported as consistent, with common side effects including constipation, gas, and burping. However, case reports and literature reviews have highlighted the potential for severe outcomes, such as the development of calcium-alkali syndrome, particularly with prolonged high-dose use. This syndrome is characterized by high calcium levels (hypercalcemia), which may affect renal function and is associated with the formation of kidney stones. Patients with pre-existing conditions like kidney disease are advised to consult a healthcare professional regarding its use.

Common questions about Alcalak (FAQ)

Q: How long can a person take Alcalak for indigestion?

Regulatory guidelines state that the maximum daily dose should not be used for more than two consecutive weeks. If your symptoms of indigestion, heartburn, or sour stomach persist for a period longer than two weeks, official instructions direct users to discontinue use and seek professional advice. The drug is intended for short-term, temporary relief.

Q: Is it normal to feel bloated or gassy after taking Alcalak?

Official information documents that gastrointestinal side effects such as flatulence (gas) and burping (eructation) are common adverse reactions. While 'bloating' is not listed explicitly, it is a type of discomfort often associated with the production of gas. This effect is related to the way the antacid neutralizes stomach acid.

Q: Can Alcalak affect the absorption of other medications I am taking?

Official product warnings state that antacids may interact with certain prescription drugs. The regulatory documents emphasize that Alcalak can alter the absorption of various other co-administered medications, primarily due to Alcalak increasing the stomach's pH level.

Q: Is there any difference between Alcalak and other calcium carbonate products like Tums?

Regulatory information indicates that Alcalak and other similar products are classified as antacids and share the same official active ingredient, Calcium Carbonate, and the same Antacid Purpose for symptom relief. Any differences may include variations in inactive ingredients, flavor, or exact dosage strength.

Q: Do foods or drinks change how Alcalak is absorbed by the body?

Official drug information notes that certain foods can affect absorption. Specifically, foods high in oxalic acid (found in spinach) or phytic acid (found in whole grains) may decrease the amount of calcium absorbed. Further information about specific dietary considerations is available in the full official label.

Q: What are the signs of taking too much Alcalak?

Taking more than the recommended dose for prolonged periods can lead to serious risks such as high calcium levels, a condition called hypercalcemia, and Milk-alkali syndrome. The potential risks documented can affect multiple body systems, including renal function.

Q: Can Alcalak be taken if I have kidney disease?

Official warnings state that individuals with kidney disease are advised to seek consultation with a doctor or pharmacist before use. Furthermore, patients with severe renal impairment (advanced kidney disease) are formally listed in official documents as a population where use is restricted due to increased safety risks.

Q: Does Alcalak interact with vitamins or mineral supplements?

Regulatory documents indicate that antacids like Alcalak may form complexes with certain substances, including some vitamins and mineral supplements like iron salts. This may result in reduced absorption of those supplements by the body.

Q: Is Alcalak used to treat conditions other than acid indigestion?

The product's stated purpose on the official Antacid label is strictly the relief of heartburn, acid indigestion, sour stomach, and upset stomach associated with these symptoms. Outside of this official drug-labeling context, the active ingredient, Calcium Carbonate, is utilized in other clinical settings as a calcium supplement or a phosphate binder.

Q: Can taking Alcalak affect my bone density?

The active ingredient, Calcium Carbonate, is utilized in other clinical settings as a calcium supplement. However, the antacid label for Alcalak does not state any intended effect on bone density. Its primary classification and purpose are for the symptomatic relief of stomach acid.

Q: Is Alcalak known to cause rebound acid production?

Rebound hyperacidity is a known effect documented in regulatory materials for the class of antacid formulations, where the sudden reduction in acid may cause the stomach to produce more acid later on. This is considered a potential side effect, especially with prolonged usage.

Q: What is the connection between Alcalak and a condition called sarcoidosis?

Official information for the active ingredient, Calcium Carbonate, lists sarcoidosis as one of the disease conditions that may require a medical consultation before use. Individuals with sarcoidosis are advised in official information to seek consultation with a healthcare professional before taking the product.

Q: Can Alcalak be taken for general stomach discomfort?

The official use of Alcalak is explicitly defined for specific symptoms: the relief of heartburn, acid indigestion, sour stomach, and associated upset stomach. The official label does not include a broader use for 'general stomach discomfort' without an underlying acid-related cause.

Q: How quickly is Alcalak expected to start working for heartburn relief?

Regulatory descriptions of the antacid class and the product’s mechanism of action emphasize the rapid nature of the relief. This rapid chemical neutralization of stomach acid means the action begins very quickly after the tablet is chewed and swallowed.

Q: Are there any long-term safety concerns associated with Alcalak use?

Yes. The most significant safety concerns are documented as being associated with long-term use or the intake of high doses. These concerns include the potential for developing hypercalcemia (high calcium levels in the blood) and a serious condition called Milk-alkali syndrome.

Q: Does Alcalak interact with common prescription antibiotics?

Official interaction statements specifically require timing separation for certain classes of antibiotics, including Fluoroquinolones and Tetracyclines. This is because Alcalak can bind to these drugs, leading to reduced absorption. This is a known interaction detailed in the product documents.

Q: Can Alcalak cause constipation or make it worse?

Constipation is explicitly listed in regulatory documents as a Common adverse reaction. This means it is an expected effect in some users, and is listed as a potential side effect for users.

Q: How is the amount of calcium in Alcalak measured?

Official product information is structured to list both the total weight of the active ingredient, which is the Calcium Carbonate salt, and the equivalent weight of Elemental Calcium that the body can use. Both figures are provided in the labeling for patient reference.

Q: Is Alcalak considered a prescription-only medicine or over-the-counter (OTC)?

Regulatory documents confirm that Alcalak is classified as an Over-the-Counter (OTC) drug. This means it is intended for non-prescription use for the self-management of immediate gastric distress symptoms stemming from excess acidity.

Q: What ingredients other than the active ingredient are in Alcalak?

The official label discloses all inactive ingredients used in the formulation. These typically include agents for coloring, flavoring, and binding the tablet. This information is provided for patient reference, especially those with conditions like Phenylketonuria (PKU).

Q: What are the main risks for people who use Alcalak for more than two weeks?

The regulatory label explicitly warns against using the maximum dosage for more than two weeks due to the risks of developing serious conditions. These conditions are hypercalcemia (high blood calcium) and the potentially serious Milk-alkali syndrome.

Q: Does Alcalak interact with stomach acid reducers like PPIs or H2 blockers?

Interactions between calcium carbonate and certain acid-reducing medicines like H2-receptor antagonists have been documented. This suggests Alcalak may decrease the blood levels of the co-administered acid reducer due to its action of increasing stomach pH.

Q: Does Alcalak contain aluminum?

Alcalak's active ingredient is Calcium Carbonate, an inorganic salt. The product is defined in regulatory documents as a single-entity Calcium Carbonate preparation, which is distinct from older categories of antacids that contain metallic salts like aluminum.

Q: How long does the relief from Alcalak usually last?

The maximum recommended single dose may be repeated every 2 to 3 hours as needed when symptoms return. This dosing frequency is documented in official directions and indicates the general duration of relief before another dose may be necessary.

Official Storage and Disposal Requirements

Alcalak (calcium carbonate) must be stored strictly according to the conditions defined in the official regulatory labeling to maintain product stability and safety.

Requirement	Specific Condition
Storage Temperature	Store at room temperature, maintained between 59^circ to 86^circF (15^circ to 30^circC).
Environmental Control	Store in a dry place.
Packaging Rules	Do not use any opened or torn tamper-evident packets.
Child Safety	Keep the product out of the reach of children.

For disposal of expired or unused tablets, regulatory guidance recommends using a drug take-back program. If a take-back program is not available, the medicine should be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed container before being thrown into the household trash, following FDA guidelines.